Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis

BACKGROUND: Atezolizumab plus chemotherapy has been recommended as a first-line treatment option for patients with advanced non-small cell lung carcinoma (NSCLC) irrespective of programmed cell death-ligand 1 (PD-L1) expression. Currently, little is known about the efficacy and treatment-related adv...

Full description

Saved in:
Bibliographic Details
Published in:Front Immunol
Main Authors: Li, Dan-Ni, Lu, Wen-Qing, Yang, Bo-Wen, Zhang, Ling-Yun, Jin, Bo, Wang, Shuo, Che, Xiao-Fang, Li, Ce, Liu, Yun-Peng, Qu, Xiu-Juan
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2021
Subjects:
Immunology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8212861/
https://ncbi.nlm.nih.gov/pubmed/34149702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.666909
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items